CN107854487A - Children's compound lysine vitamin calcium medicine compound comprising chiral photo-isomerisation compound and application thereof - Google Patents
Children's compound lysine vitamin calcium medicine compound comprising chiral photo-isomerisation compound and application thereof Download PDFInfo
- Publication number
- CN107854487A CN107854487A CN201610843576.3A CN201610843576A CN107854487A CN 107854487 A CN107854487 A CN 107854487A CN 201610843576 A CN201610843576 A CN 201610843576A CN 107854487 A CN107854487 A CN 107854487A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- lysine
- calcium
- compound
- solvated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims abstract description 178
- 150000001875 compounds Chemical class 0.000 title claims abstract description 142
- 239000004472 Lysine Substances 0.000 title claims abstract description 119
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 239000011575 calcium Substances 0.000 title claims abstract description 87
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 87
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940088594 vitamin Drugs 0.000 title claims abstract description 19
- 229930003231 vitamin Natural products 0.000 title claims abstract description 19
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 19
- 239000011782 vitamin Substances 0.000 title claims abstract description 19
- 150000003722 vitamin derivatives Chemical class 0.000 title claims abstract description 18
- 238000006317 isomerization reaction Methods 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 114
- 206010006956 Calcium deficiency Diseases 0.000 claims abstract description 8
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 7
- 230000012010 growth Effects 0.000 claims abstract description 6
- 208000007442 rickets Diseases 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 168
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 163
- 229960003646 lysine Drugs 0.000 claims description 116
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 87
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 86
- 239000011691 vitamin B1 Substances 0.000 claims description 86
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 84
- 229930003268 Vitamin C Natural products 0.000 claims description 84
- 235000019154 vitamin C Nutrition 0.000 claims description 84
- 239000011718 vitamin C Substances 0.000 claims description 84
- 239000011716 vitamin B2 Substances 0.000 claims description 81
- 239000011653 vitamin D2 Substances 0.000 claims description 65
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 claims description 58
- 239000002075 main ingredient Substances 0.000 claims description 30
- 229960005357 lysine acetate Drugs 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 239000000052 vinegar Substances 0.000 claims description 7
- 235000021419 vinegar Nutrition 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 230000002584 immunomodulator Effects 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 206010021135 Hypovitaminosis Diseases 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 abstract description 97
- 150000002669 lysines Chemical class 0.000 abstract description 2
- 230000006978 adaptation Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 85
- 235000001465 calcium Nutrition 0.000 description 75
- 239000000243 solution Substances 0.000 description 70
- 239000000843 powder Substances 0.000 description 50
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000005516 engineering process Methods 0.000 description 34
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 33
- 235000020985 whole grains Nutrition 0.000 description 32
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 30
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 30
- 235000010447 xylitol Nutrition 0.000 description 30
- 239000000811 xylitol Substances 0.000 description 30
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 30
- 229960002675 xylitol Drugs 0.000 description 30
- 238000004806 packaging method and process Methods 0.000 description 29
- 229930003316 Vitamin D Natural products 0.000 description 27
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 27
- 238000000034 method Methods 0.000 description 27
- 239000011710 vitamin D Substances 0.000 description 27
- 235000019166 vitamin D Nutrition 0.000 description 27
- 150000003710 vitamin D derivatives Chemical class 0.000 description 27
- 229940046008 vitamin d Drugs 0.000 description 27
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 26
- 238000005469 granulation Methods 0.000 description 25
- 230000003179 granulation Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 239000001257 hydrogen Substances 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 21
- 238000011049 filling Methods 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 18
- 239000002245 particle Substances 0.000 description 18
- 239000002131 composite material Substances 0.000 description 17
- 238000007789 sealing Methods 0.000 description 17
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 16
- 229910052782 aluminium Inorganic materials 0.000 description 16
- 210000004379 membrane Anatomy 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000008108 microcrystalline cellulose Substances 0.000 description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 12
- 239000011574 phosphorus Substances 0.000 description 12
- 229910052698 phosphorus Inorganic materials 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 229920001285 xanthan gum Polymers 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 239000007887 hard shell capsule Substances 0.000 description 8
- 229960005337 lysine hydrochloride Drugs 0.000 description 8
- 235000015424 sodium Nutrition 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010020597 Hyperchloraemia Diseases 0.000 description 7
- 238000007605 air drying Methods 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- -1 LYS L- Lysine Acetates Chemical class 0.000 description 6
- 208000005374 Poisoning Diseases 0.000 description 6
- 241000220317 Rosa Species 0.000 description 6
- 229930003270 Vitamin B Natural products 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 231100000572 poisoning Toxicity 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000011720 vitamin B Substances 0.000 description 6
- 235000019156 vitamin B Nutrition 0.000 description 6
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 235000012730 carminic acid Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000004376 Sucralose Substances 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 238000010074 rubber mixing Methods 0.000 description 4
- 239000011122 softwood Substances 0.000 description 4
- 235000019408 sucralose Nutrition 0.000 description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010027417 Metabolic acidosis Diseases 0.000 description 3
- 244000228451 Stevia rebaudiana Species 0.000 description 3
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- BVHLGVCQOALMSV-UHFFFAOYSA-N (5-amino-1-carboxypentyl)azanium;chloride Chemical class Cl.NCCCCC(N)C(O)=O BVHLGVCQOALMSV-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 241000370738 Chlorion Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000029422 Hypernatremia Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 239000000576 food coloring agent Substances 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- BVHLGVCQOALMSV-NUBCRITNSA-N D-lysine hydrochloride Chemical class Cl.NCCCC[C@@H](N)C(O)=O BVHLGVCQOALMSV-NUBCRITNSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010059491 Intracranial haematoma Diseases 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000024637 distal renal tubular acidosis Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical class COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides the application in the vitamin lysine comprising chiral photo-isomerisation compound of prevention or treatment people and mammal L lysines shortage, calcium deficiency, retarded growth, rickets, osteoporosis etc. and the health food or medicine of calcium composition so that product has more new adaptation population or more preferable specific aim and more preferable clinical safety etc. on Clinical practice.
Description
Technical field
The present invention relates to pharmaceutical technology field, is specifically to provide prevention or treatment calcium deficiency, promotes normal growth hair
Educate, the patient that rickets, osteoporosis or 1B lack supplements 1B or metabolic acidosis, hyperchloremia
But need to replenish the calcium or the lysine vitamin calcium medicine compound comprising chiral photo-isomerisation compound of lysine etc. or say that compound relies
Propylhomoserin ties up calcium medicine or says the pharmaceutical composition and its preparation and use of children's compound lysine.
Background technology
Calcium ion is the indispensable ion of body items physiological activity.It is for maintaining the biological electricity of cell membrane both sides
Position, maintains normal Nerve conduction etc., some functions of hormones mechanism are showed by calcium ion.Main function or
Mechanism is:
1st, calcium ion is clotting factor, participates in coagulation process.2nd, muscle (including skeletal muscle, smooth muscle) is participated in shrink
Journey, promote heartbeat.3rd, neurotransmitter synthesis and release, hormone sensitive lipase gene and secretion, and afferent nerve signal are participated in.Work as body
During calcium deficiency, the release of neurotransmitter is obstructed, and the excitation mechanism and suppression mechanism of human body are destroyed.If children lack
Calcium, the meeting morbid night crying of babies, sleep terror fright at night, irritated insomnia, serious causes brain development obstacle, slow in reacting, more dynamic, difficulty of learning etc. occurs
Disease, influence brain maturation and intelligence.4th, it is the important substance of bone composition.5th, signal of resisting the enemy is transmitted.Its mechanism is:When external anti-
Original activation φt cell receptor, starts the signal path of calcium-mediated, promotes immune cell differentiation and growth.When germ, carefully
When the foreign invaders such as bacterium, poisonous substance invade human body, calcium ion sends pre-warning signal first;Subsequent calcium ion sends invader again to be had
The signal of what characteristic, immune system organize corresponding immunocyte, capture and phagocytosis enemy therewith.Once calcium deficiency, Jiu Huifa
Raw function of immune system declines, is disorderly, triggers disease.Such as:Autoimmune disease lupus erythematosus, rheumatism;Skin disease:Skin
Inflammation, acne etc..Replenish the calcium, played an important role to treating these diseases, the function for calcium of having given counterevidence.
However, generally Oral Calcium Preparations only 1/5~1/3 are by intestinal absorption, the plasma protein binding rate about 45% of calcium, oral calcium
Agent about 80% is drained from excrement.
Lysine category basic amino acid, there are three kinds of DL lysines, D-Lys, 1B citation forms, 1B
It is one of necessary 8 kinds of amino acid of human body, 1B provides structural constituent for synthetic carnitine, and carnitine can promote fat in cell
The synthesis of acid.It is higher to the requirement of 1B particularly in child development phase, after being ill convalescence, pregnant lactication phase.Due to
Content is relatively low in the foods such as rice, corn, easily causes human body shortage, is referred to as " the first lack amino acid ".
1B, which lacks, can cause depauperation, poor appetite, weight loss, negative nitrogen balance, Hypoproteinemia, tooth
Depauperation, anaemia, enzymatic activity declines and other physiological function obstacles.1B is improved intelligence, promotes growth, reinforcement
Matter;Improve a poor appetite, improve malnutritive situation;Improve insomnia, improve memory;Help produces antibody, hormone and enzyme, and raising is exempted from
Epidemic disease power, increase hemochrome;The absorption of calcium is helped, treatment prevents osteoporosis;Nerve fiber reparation is helped, promotes nerve cell
Regeneration, improve the effect of central nervous tissue function.Lysine can improve blood-brain barrier permeability, contribute to medicine to enter brain thin
Intracellular, clinic are used as treatment craniocerebral trauma, chronic brain tissue ischemia, the cerebral protective agent of ischemic disease, or to other encephalopathics
Auxiliary treatment, it can also be used to 1B lack caused by children's poor appetite, malnutritive and atelencephalia (Liu Xiaolan,
Deng, the medical applications new development of 1B, the modern clinical practice magazine of China, 2006 (3) 8:923-924).
Vitamin D2Promote absorption and reabsorption phosphorus of the small intestinal mucosa brush border to calcium, it is dense to improve blood calcium, serium inorganic phosphorus
Degree, collaboration parathyroid hormone (PTH), calcitonin (CT), promote old bone release calcium phosphate, maintain and adjust plasma calcium, phosphorus just
Normal concentration;Calcific deposit can be promoted citrate is deposited in bone in new bone formation position, promote bone calcification and Gegenbaur's cell work(
Can be ripe with osteoid tissue.Absorption of the human body to calcium, phosphorus is improved, promotes growth and bone calcification, promotes tooth to perfect, firm bone
Bone, prevent children rachitis and senile osteoporosis, reduce the tolerance to insulin, reduce women and suffer from senile dementia
Risk.
Vitamin B1Necessary to being human energy metabolism and glycometabolism, and heart is maintained, nerve and digestive system are just
Necessary to Chang Gongneng.
At present, the disclosed document report composite preparation (document of children's compoundL -lysine granules:Children's compound relies ammonia
Granulates, national drug standards WS-10001- (HD-0920) -2002), it is mainly used in the nutrition for improving baby and children
It is bad, it is in poor health to wait disease, children, pregnant woman's supplement calcium.Its dosage usage:Generally, orally.Less than 3 years old:One time 1/
2 bags;4~7 years old:One time 1 bag;8~14 years old:One time 1~2 bag.1~2 time on the one or follow the doctor's advice.Warm boiled water.
But there has been no open source literature report LYS L- Lysine Acetates or Lysine Acetate or lysine or L-
The composition of children's compound lysine of lysine, it also there is no the composition of high content or new height in reported literature unit formulation
The composition that weight is formed, there has been no unit dose lysine hydrochloride and calcium monohydrogen phosphate 154mg/108mg, 231mg/162mg
And contain vitamin B1, vitamin B2, vitamin C, vitamin D2Composition etc..Many deficiencies be present in the preparation of prior art,
D-Lys and 1B containing half in its lysine hydrochloride, only 1B is just easily absorbed by organisms utilization, to people
Body has larger value, and D-Lys are not easy the utilization that is absorbed by the body;Although also disclose report title at present to limit
For the L lysine HCL granule of single optical isomer, but it is only limitted to one-component administration.It is in addition, small in prior art
There is also the trouble for being not suitable for hyperchloremia, acid poisoning and renal insufficiency etc. in some cases for the agent of youngster's compoundL -lysine granules
Person, especially unknown in advance or take in the case of being difficult to know and may bring adverse consequences;Chlorion was taken in multipair self-closing
Disease children are unfavorable;And do not limited in current preparation and use 1B, this causes the quality of preparation or nutrition or treatment
It is worth or is restricted or Optimal State can not be in;Furthermore preparation of the current composition when increasing a multiple dose unit
In, increase half is not easy the D-Lys being absorbed and used, and a unit dose is bigger, and Time of Administration is longer, wastes bigger.This
So that manufacture, it is convenient to take on, transport and packaging on there is also problem or can not to the greatest extent be suitable to clinical practice, be less useful for saving
About human resources and build a resource-conserving society, this rough sledding is ignored and improved always for many years, actual
It is the wasting of resources, unnecessary packaging simultaneously increases pressure to environmental protection, but there is not yet breaking through old framework.【Hyperchloremia or height
The bibliography of chloremia or acid poisoning etc.:Document 1, Li Zhaoquan, 12 clinics of intracranial hematoma complicated by postoperative hypernatremia
Analysis, practical sacred disease magazine, 05 phase in 2005, p.44-45;Document 2, Zhang Xuejun, Chen Zhiqin, Li Hua are high after cerebral hemorrhage
The clinical research of sodium hyperchloremia, apoplexy and sacred disease magazine, the 5th phase of volume 24 in 2007, p.609-611;Document 3, season
Hamming, 11 heavy head-brain injuries merge hyperglycaemia, hypernatremia, hyperchloremia experiences on diagnosis and treatment, Jiangsu Clinical Medical Journals, 1998 years the
The phase of volume 2 the 6th, p.505,507;Document 4, Yin Peida, the pathogenesis of distal renal tubular acidosis, foreign medical science (clinical practice
Fascicle), phase nineteen eighty-two 12;Document 5, Zhou Hui, etc., the control strategy of third ventricle in children Postoperation Complications of Craniophryngioma, clinic
Neurosurgery magazine, 05 phase in 2011;Document 6, Zhou Lei, etc., 12 RTA patient Analysis Initial Misdiagnosis and nursing,
Chinese Quotation Analysis, 17 phases in 2005;】.
The content of the invention
Involved in the present invention is the compound lysine dimension calcium or children's compound lysine for including chiral photo-isomerisation compound
Composition and its preparation and use, and in particular to be prevention or treat calcium deficiency LYS or L- Lysine Acetates
Or Lysine Acetate or lysine or 1B and vitamin and the composition and its preparation and use of calcium.
The compound lysine dimension calcium of the present invention or the composition of children's compound lysine:One unit dose or unit formulation
Said composition in main ingredient component weight or weight ratio be:LYS 35~231mg or L- Lysine Acetate or vinegar
30~185mg of sour 40~261mg of lysine or lysine or 1B or its solvated compounds, calcium monohydrogen phosphate or calcium monohydrogen phosphate
2 25~162mg of hydrate, vitamin D2Or its unit of solvated compoundses 40~240, vitamin B1Or vitamin B1Monohydrate
Or 0.35~2.31mg of its solvated compounds is (with without hydrate weight calculation amount;Its solvated compounds includes vitamin B1One hydration
Thing), vitamin B2Or 0.20~1.38mg of its solvated compounds, 15.0~92.4mg of vitamin C or its solvated compounds, each group
Point solvated compoundses weight in addition to specifying, to be converted into solvent-free chemical combination when calculated weight;Wherein, L- hydrochloric acid relies
Propylhomoserin or L- Lysine Acetates or Lysine Acetate or lysine or 1B or vitamin D2Or vitamin B1Solvent chemical combination
Calculated weight when being converted into solvent-free chemical combination according to it.The weight of the solvated compoundses of each component in addition to specifying, with
Calculated weight when being converted into solvent-free chemical combination.
Further, the composition of compound lysine of the invention dimension calcium or children's compound lysine:One unit dose or
The weight of main ingredient component or weight ratio are in the said composition of unit formulation:LYS 38.5~231mg or L- acetic acid
Lysine or 43~261mg of Lysine Acetate or lysine or 30~185mg of 1B or its solvated compounds, calcium monohydrogen phosphate
Or 27~the 162mg of hydrate of calcium monohydrogen phosphate 2, vitamin D2Or its unit of solvated compoundses 40~240, vitamin B1Or vitamin
B1Monohydrate or or 0.385~2.31mg of its solvated compounds (with without hydrate weight calculation amount), vitamin B2Or its solvent chemical combination
0.23~1.38mg of thing, 15.4~92.4mg of vitamin C or its solvated compounds, and pharmaceutically acceptable one or more
Auxiliary material or carrier;Wherein, the weight of the solvated compoundses of each component is in addition to specifying, to be converted into solvent-free chemical combination when in terms of
Weight is calculated, solvated compoundses include hydrate.
Equipped with the present invention in the packaging unit or independent packaging individual of independent a medicine or healthy food
Weight than the total amount of composition can arbitrarily change, can with 3 daily doses or 5 daily doses or 6 daily doses or one week or
10 daily doses or 12 days, 20 days, 28 days, 30 days, 60 days, the dosage such as 100 days etc. and change or adjustment, this is without departing from the present invention
Spirit.
The compound lysine dimension calcium of the present invention or the composition of children's compound lysine can more preferably be:One unit dose
In composition in amount or unit formulation containing LYS or its solvated compounds 38.5mg or L- Lysine Acetates or
Lysine Acetate or its solvated compounds 43.47mg or 43.5mg or 44 or lysine or 1B or its solvated compounds
30.08mg or 30.1mg or 30mg, calcium monohydrogen phosphate or the hydrate 27mg of calcium monohydrogen phosphate 2, vitamin D2Or its solvated compounds 40
Unit, vitamin B1Or vitamin B1Monohydrate or its solvated compounds 0.385mg (with without hydrate weight calculation amount), vitamin
B2Or its solvated compounds 0.23mg, vitamin C or its solvated compounds 15.4mg, and it is pharmaceutically acceptable a kind of or more
Kind auxiliary material or carrier;The wherein weight of the solvated compoundses of each component in addition to specifying, to be converted into solvent-free chemical combination when
Calculated weight.
The present invention compound lysine dimension calcium composition can also more preferably be:In one unit dose or unit formulation
Composition in containing LYS or its solvated compounds 77mg or L- Lysine Acetates or Lysine Acetate or its is molten
Immunomodulator compounds 86.945mg or 86.95mg or 87mg or lysine or 1B or its solvated compounds 61.63mg or
61.6mg or 62mg, calcium monohydrogen phosphate or the hydrate 54mg of calcium monohydrogen phosphate 2, vitamin D2Or its unit of solvated compoundses 80, dimension life
Plain B1Or vitamin B1Monohydrate or or its solvated compounds 0.77mg (with without hydrate weight calculation amount), vitamin B2Or its is molten
Immunomodulator compounds 0.46mg, vitamin C or its solvated compounds 30.8mg, and pharmaceutically acceptable one or more auxiliary materials or
Carrier;Wherein, the weight of the solvated compoundses of each component is in addition to specifying, to be converted into solvent-free chemical combination when calculate weight
Amount.
The present invention compound lysine dimension calcium composition can also more preferably be:In one unit dose or unit formulation
Composition in containing LYS or its solvated compounds 154mg or L- Lysine Acetates or Lysine Acetate or its is molten
Immunomodulator compounds 173.89mg or 173.9mg or 174mg or lysine or 1B 123.26mg or 123.3mg or 123mg, phosphorus
The sour hydrate 108mg of hydrogen calcium or calcium monohydrogen phosphate 2, vitamin D2Or its unit of solvated compoundses 160, vitamin B1Or vitamin B1
Monohydrate or or its solvated compounds 1.54mg (with without hydrate weight calculation amount), vitamin B2Or its solvated compounds
0.92mg, vitamin C or its solvated compounds 61.6mg, and pharmaceutically acceptable one or more auxiliary materials or carrier;Its
In, the weight of the solvated compoundses of each component in addition to specifying, to be converted into solvent-free chemical combination when calculated weight.The present invention
Higher unit dose or the composition of unit formulation be advantageous to save manufacturing time and manufacturing expense at double, save packaging material,
Be advantageous to environmental protection.
The present invention compound lysine dimension calcium composition can also be:Combination in one unit dose or unit formulation
Contain LYS or its solvated compounds 231mg or L- Lysine Acetates or Lysine Acetate or its solvent chemical combination in thing
Thing 260.83mg or 260.8mg or 261mg or lysine or 1B or its solvated compounds 184.89mg or 184.9mg or
185mg, calcium monohydrogen phosphate or the hydrate 162mg of calcium monohydrogen phosphate 2, vitamin D2Or its unit of solvated compoundses 240, vitamin B1Or
Its solvated compounds 2.31mg, vitamin B2Or its solvated compounds 1.38mg, vitamin C or its solvated compounds 92.4mg,
And pharmaceutically acceptable one or more auxiliary materials or carrier;Wherein, the weight of the solvated compoundses of each component is removed and referred in particular to
Calculated weight when calmly outside, to be converted into solvent-free chemical combination;80- of the above each component in the labelled amount of its main ingredient constituent content
120% is also possible.
Or above-mentioned each main ingredient component in the different compositions of said one unit dose or a unit formulation
0.5-5 times etc., and part of (or increasing or decreasing) each component can be calculated according to same ratio with 0.5 for minimum multiple unit
Number (0.5 times, 1 times, 1.5 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times etc.).
It is pointed out that the main ingredient component contained in composition in a unit dose or a unit formulation or its
The weight ratio of main ingredient component is:The 43.47mg or 43.5mg of L- Lysine Acetates or Lysine Acetate or its solvated compounds or
Between 44mg, or between lysine or 1B or the 30.08mg or 30.1mg or 30mg of its solvated compounds;Or L- acetic acid
Between lysine or the 86.945mg or 86.95mg or 87mg of Lysine Acetate or its solvated compounds, or lysine or L- rely
Between the 61.63mg or 61.6mg or 62mg of propylhomoserin;Or L- Lysine Acetates or Lysine Acetate or its solvated compounds
Between 173.89mg or 173.9mg or 174mg, or the 123.26mg of lysine or 1B or its solvated compounds or
It is equivalent or approximate effects equivalent in the present invention between 123.3mg or 123mg, or between their any multiple, because
Effective digital is different and has omitted or has accepted or rejected;The effective digital of main ingredient or auxiliary material is accepted or rejected in other compositions of the present invention
Mode or principle are also identical with this.
For the pharmaceutical composition of the present invention, can contain in the composition in a unit dose or a unit formulation
The LYS or L- Lysine Acetates or Lysine Acetate or lysine or 1B of high dose are (in terms of anhydride
Calculate), or calcium monohydrogen phosphate or the hydrate of calcium monohydrogen phosphate 2 or vitamin B1, vitamin B2, vitamin C, vitamin D2, this is according to different
Indication or crowd or the patient of all ages and classes depending on and aspect manufacture, transport or carry, reducing manufacturer's time takes
With, reduce packing charges or freight or convenient to take at double.The composition of high unit dose is advantageous to significantly reduce auxiliary material
Dosage and improve production efficiency etc..
In the pharmaceutical composition of the present invention, the type of service of different component can be different, such as:LYS or L- vinegar
Sour lysine or Lysine Acetate or lysine or 1B can use its crystalline hydrate (LYS or L-
Lysine Acetate or the hydrate of Lysine Acetate 1,2,3 etc.);Calcium monohydrogen phosphate and its crystalline hydrate, such as the hydrate of calcium monohydrogen phosphate 2
Deng if using its anhydride, its content or inventory can be rolled over accordingly according to molecular weight according to the hydrate of calcium monohydrogen phosphate 2
Calculate;This without prejudice to other components using or without using, when deployed, can according to chemistry or pharmacy rule carry out.
In the pharmaceutical composition of the present invention, the amount of each component or the different pharmaceutically acceptable form (bags of each component
Include its salt or hydrate) present invention provide that certain limit in rationally can change or adjust, to form different combinations.
The purposes performance of the composition of the compound lysine dimension calcium of the present invention is:Said composition is independent or can be connect with pharmacy
The auxiliary material received, the application in tablet, granule, capsule, powder, supensoid agent, liquid preparation is prepared.
The LYS or L- Lysine Acetates or Lysine Acetate or lysine or 1B and phosphorus of the present invention
Sour hydrogen calcium or calcium monohydrogen phosphate 2 hydrate, vitamin B1, vitamin B2, vitamin C, vitamin D2Composition, also can dosing
Upper acceptable auxiliary material is prepared into pharmaceutical preparation, including (ordinary tablet, dispersible tablet, chewable tablets, effervescent tablet, mouth collapse for capsule, tablet
Piece etc.), granule, powder, supensoid agent etc.;Its preparation method is that LYS or L- Lysine Acetates or acetic acid are relied into ammonia
Acid or lysine or 1B and calcium monohydrogen phosphate or the hydrate of calcium monohydrogen phosphate 2, vitamin D2, vitamin B1And pharmaceutically may be used
Receive auxiliary material to be prepared in accordance with the law.Wherein, pharmaceutically acceptable auxiliary material includes filler, lactose, starch, microcrystalline cellulose;Collapse
Solve agent such as hydroxypropul starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl starch, sodium carboxymethylcellulose, crosslinked polyethylene pyrrole
Pyrrolidone, Guar natural gum, the one or several kinds of methylcellulose;Lubricant such as magnesium stearate, zinc stearate, superfine silica gel powder, cunning
The one or several kinds of stone flour, polyethylene glycol 2000-8000;Pharmaceutically acceptable flavouring and/or colouring agent (such as Aspartame,
Honey element, saccharin sodium, Sucralose, STEVIA REBAUDIANA element, xylitol, sorbierite, xylose, lactose, glycyrrhizin, sucrose, citrus seed oil,
Orange oil, lemon oil, peppermint oil, linalool, menthol, curcumin, monascorubin, beet red, amaranth, acid red, sunset
Huang, Gardenia Yellow, chlorophyll, famille rose, food coloring is red or food coloring uranidin or other pharmaceutically acceptable colors
Element etc., other pharmaceutically acceptable sweeteners or orange essence, flavoring apple essence, mango essence or other pharmaceutically acceptable
Essence) or pharmaceutically acceptable preservative or mould inhibitor or bacteriostatic agent (benzoic acid or its sodium or sylvite, sorbic acid or its
Pharmaceutical salts, potassium sorbate or sodium sorbate, nipagin esters etc.) etc. in one or more.
The preparation method of solid pharmaceutical preparation includes, and supplementary material is crossed into 60~200 mesh sieves respectively, and the L- hydrochloric acid after sieving is relied into ammonia
Acid or L- Lysine Acetates or Lysine Acetate or lysine or 1B and calcium monohydrogen phosphate or the hydrate of calcium monohydrogen phosphate 2, dimension
Raw plain B1, vitamin B2, vitamin C, vitamin D2It is well mixed with auxiliary material, carries out dry granulation or with 2-10% adhesive systems
Into softwood, the granulation of 14~100 mesh sieves is crossed, 40~80 DEG C of dryings, crosses 14~100 mesh sieve whole grains, add disintegrant and lubricant stearic
Sour magnesium, zinc stearate, superfine silica gel powder, talcum powder, the one or several kinds of polyethylene glycol 2000-8000 (add when preparing supensoid agent
Pharmaceutically acceptable suspending agent or stabilizer, such as xanthans, tartaric acid, citric acid, tragacanth, gelatin, fructose, polyethylene
Pyrrolidones, methylcellulose, ethyl cellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, sodium alginate, carboxymethyl form sediment
One or several kinds in powder sodium, pectin etc. are well mixed, survey granule content, in Filling bag), tabletting or encapsulated, packaging, inspection
Test, obtain finished product;Wherein, vitamin D2Be mixed into or mix can with ethanol dissolve vitamin D2Solution is added to or is injected to afterwards
Mixed in the mixture of other main ingredients or main ingredient and auxiliary material, or use vitamin D2With the premixing of pharmaceutically acceptable auxiliary material
Thing in the mixture of other main ingredients or main ingredient and auxiliary material with mixing, then granulation etc..
The LYS or L- Lysine Acetates or 1B and calcium monohydrogen phosphate of the unit dose of the present invention
The composition phase of other three components such as composition and a same unit dose lysine hydrochloride etc. other three components
Under similar circumstances or it can avoid being not easy to be immediately used by the body D- lysine hydrochlorides using a half-value dose than, medicine of the present invention,
This means in the case of same quality, composition of the invention can not only provide a multiple dose more under square one
The L-type lysine that human body first lacks, moreover it is possible to avoid or limit half and be not easy to be absorbed by organisms the D type isomers utilized, can carry
Efficiency of transhipment calcium ion etc. etc. is risen.
Therefore, the present invention not only not only itself provides in the preparation of a unit dose is more available for what human body utilized
The lysine of L-configuration, additionally aid and improve the absorption of calcium and the utilization rate by body on the original basis, produce preferably collaboration
Effect.This also causes the patient for calcium deficiency, for sufferers of osteoporosis face, in same situation, is preferably replenished the calcium obtaining
Effect.Being multiplied for L-type lysine in this unit dose, it is also for the patient of cranial vascular disease to a certain extent
With positive effect.
During production unit dosage particles, under square one, help exponentially to produce within the unit interval
Go out LYS or L- Lysine Acetates in unit dose formulations or the high preparation or composition of 1B content, significantly
Ground reduces production cost and cost of transportation etc..
Therefore, for the composition for being relatively fixed dosage, for the unit formulation or unit of a new composition
The children and adult that the calcium preparation containing further amounts of 1B either lacks for calcium and 1B in dosage, still
Positive meaning is had more for the calcium preparation containing 1B, when manufacturing the composition of high standard or high dose, at double
Processing charges, packing charges and freight are saved, is also reduced environmental pollution and treatment of wastes produced, is contributed to environmentally friendly
The construction of society.
It was found that the different L- Lysine Acetates of the present invention or children's compound lysine of Lysine Acetate tie up calcium
The pH value of main ingredient composition is more meaningful closer to physiology or to acid poisoning patient.For prior art, at about 25 DEG C, claim respectively
By lysine hydrochloride, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, vitamin D2(respectively by weight
77mg:54mg:0.77mg:0.46mg:30.8mg:80 unit samples), about 5 grams are taken in 50ml flasks, add 20ml injections
Water, it is sufficiently stirred or shakes 20 minutes after placing, tests the pH value of its liquid;Meanwhile for the composition of the present invention, take respectively
Embodiment 7, embodiment 8, embodiment 16, embodiment 17, embodiment 18, embodiment 19, embodiment 20, embodiment 24, embodiment
25th, embodiment 30, about 5 grams of the powder of six main ingredient components of the shown ratio of embodiment 31 are respectively placed in 50ml flasks, are added
20ml waters for injection, it is sufficiently stirred or shakes 20 minutes after placing, tests the pH value of its liquid;As a result find embodiment 7, implement
Example 8, embodiment 16, embodiment 17, embodiment 18, embodiment 19, embodiment 20, embodiment 24, embodiment 25, embodiment 30,
The pH value of embodiment 31 than prior art lysine hydrochloride children's compoundL -lysine granules pH of the composition in water
Value is big, and closer to Human Physiology neutral value, thus more preferably or advantageously, to body more beneficial to some.In addition, especially
It is the patient to acid poisoning, the exacerbation of symptoms of metabolic acidosis can be made by being further added by the concentration of chlorion in body, in light
The patient of the renal failure of degree.It is more meaningful in the situation or improvement acidic constitution of acid poisoning.The lysine or L- of alkalescence rely
Propylhomoserin tends to the L- Lysine Acetates of alkalescence or Lysine Acetate is more more valuable than lysine hydrochloride or more preferable security.Cause
And LYS of the invention or lysine or 1B or L- Lysine Acetates or Lysine Acetate and vitamin and
The composition that calcium is formed is with more reality and Long Significance or clinical value, especially in terms of potential adverse reaction is prevented.
The invention provides it is improved or more have advantage compound lysine dimension calcium or children's compound lysine medicine group
Compound, the present invention also embody further advantage and are simultaneously:The 1st, one LYS and calcium monohydrogen phosphate, vitamin B are provided1, dimension
Raw plain B2, vitamin C, vitamin D2New ratio composition, provide in a unit dose and more effectively can absorb
The 1B utilized, contribute to growing for children etc.;The 2nd, L- Lysine Acetates and calcium monohydrogen phosphate, vitamin B are provided1、
Vitamin B2, vitamin C, vitamin D2New ratio composition, reduce the incidence of hyperchloremia;3rd, provide lysine or
1B and calcium monohydrogen phosphate, vitamin B1, vitamin B2, vitamin C, vitamin D2Composition, reduce high during clinical administration
The potential incidence that chloremia occurs;4th, the composition containing lysine hydrochloride is unfavorable for controlling for autism children
Treat, to the self-closing disease but patient of the pharmaceutical composition that requires supplementation with lysine and calcium and vitamin, there is provided one more pacifies
Effective or more selection entirely, this more current pharmacy or clinic are ignored or have no promotion;5th, for having occurred or easily having sent out
The patient of raw acid poisoning provides new selection, or reduces potential adverse reaction.6th, higher unit dose of the invention or list
The composition of position preparation is advantageous to save manufacturing time and manufacturing expense at double, particularly in the case where equipment capacity is certain,
Cause work time cost to be multiplied, again to the packaging for having more one or several times, bring pressure to environment, the present invention provides high unit dose
The preparation of the composition of amount, to one times of the insoluble drug release of the equal daily dose of the manufacturing or the production capacity of several times and environment is become
Close friend, packaging material is saved, is advantageous to environmental protection.7th, the composition of relatively low unit dose of the invention or unit formulation is advantageous to
Supplementary material loss is saved at double, avoids abandoning waste, while to take to bring convenience, more favorable clinical safe administration.8th, originally
Invent the 1B and calcium monohydrogen phosphate vitamin B obtained1, vitamin B2, vitamin C, vitamin D2Composition, preparation rule
Lattice identical LYS or L- Lysine Acetate calcium monohydrogen phosphate vitamin Bs1, vitamin B2, vitamin C, vitamin D2's
Composition piece is than the lysine hydrochloride of preparation specification identical racemization and the vitamin B of calcium monohydrogen phosphate1, vitamin B2, vitamin C,
Vitamin D2Composition is more easy to rapidly enter blood circulation system and reaches effective treatment concentration, has more obvious clinical excellent
Gesture.The 9th, the composition of high content or the preparation of high drug content of new unit dose are provided, save the moneys such as inspection, transport at double
Source.
The present invention composition, suitable for prepare be used for prevent and treat people and mammal retarded growth,
Teenager, pregnant woman, old man, calcareous supplement, hypovitaminosis, rickets, osteoporosis or the 1B of calcium deficiency patient lack
Weary patient supplements 1B or metabolic acidosis, hyperchloremia but needs to replenish the calcium or vitamin or lysine etc. and promote
The application entered in the medicine or health food to grow.
Embodiment
Except in embodiment and when indicated otherwise, all numerical value used should be by specification and claims
It is interpreted as being modified with term " about " in all examples, therefore, unless the contrary indication, this specification and appended
The numerical parameter gone out given in claims is approximation, the required property that it can be according to sought by by present disclosure
Matter and change, at least, and not be intended to limit the application of doctrine of equivalents right, each numerical parameter takes an examination
The number and routine for considering effective digital round up method to explain.
Although the number range and parameter that set the wide scope of disclosure are approximations.But institute in a particular embodiment
The numerical value provided is reported as precisely as possible, and any number is substantially comprising some by finding in their own test
The error that standard deviation is necessarily led to.
It is pointed out that unless in text clearly in addition explanation, used in this specification and the appended claims
Singulative "one", " one kind " and "the" include the plural form of referring to thing, so, such as.If refer to containing " one
Mixture including two or more compounds during the composition of kind compound ", it is further noted that unless herein clearly
Ground illustrates that term "or" generally includes "and/or" in addition.
Drug content in each embodiment can be according to the 90-110% of its labelled amount or the 85-115% of labelled amount
Qualified specification.
" pharmaceutical composition " used herein refers to the composition of medicine, and described pharmaceutical composition can contain at least one
Pharmaceutically acceptable carrier.
" pharmaceutically acceptable excipient " used herein refers to the medicine that the compound for being applied to occasionally provide herein is administered
With carrier or solvent, it is included well known to a person skilled in the art any examples of such carriers suitable for specific administration mode,
In order to further appreciate that the present invention, the preferred embodiment of the invention is described with reference to embodiment, still
It should be appreciated that these descriptions are simply further explanation the features and advantages of the present invention, rather than to the claims in the present invention
Limitation.
The preparation of the children's compound lysine capsule of embodiment 1, (prescription:1000):LYS 38.5g, phosphorus
The sour hydrate 27g of hydrogen calcium 2, vitamin D240000 units, vitamin B10.385g, vitamin B20.23g, vitamin C
15.4g, microcrystalline cellulose 40g, pregelatinized starch 5g, low-substituted hydroxypropyl methylcellulose 10g, superfine silica gel powder 1g;
Take recipe quantity, respectively cross 100 mesh sieves LYS, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, dimension life
Plain B2, vitamin C, microcrystalline cellulose, pregelatinized starch, low-substituted hydroxypropyl methylcellulose mixed according to equal increments method it is equal
It is even, take vitamin D2Dissolved with appropriate absolute ethyl alcohol, the solution that concentration is about 0.8mg/ml is made, in raw material fine powder uniformly
Above-mentioned solution is sprayed into, is mixed, about 2mm thin strip dry plate is pressed into dry-pressing formula rubber mixing machine, crosses the granulation of 20 mesh sieves, 40 DEG C of air blast
Dry 2 hours, taken out after drying, add the superfine silica gel powder of recipe quantity, mix, cross 20 mesh sieve whole grains, survey main ingredient L- hydrochloric acid in particle
The content of lysine, it is according to dosage filling in hard shell capsules, packaging, examine, obtain product.
The children's compound lysine of embodiment 2 ties up the preparation of calcium capsule agent, (prescription:1000):LYS 77g,
The hydrate 54g of calcium monohydrogen phosphate 2, vitamin D280000 units, vitamin B1Monohydrate 0.77g (with without hydrate weight calculation amount),
Vitamin B20.46g, vitamin C 30.8g;Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves LYS
With the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C be well mixed according to equal increments method, by the dimension of recipe quantity
Raw plain D2Dissolved with appropriate absolute ethyl alcohol, the solution that concentration is about 1mg/ml is made, it is thin that above-mentioned solution is uniformly sprayed into raw material
In powder, mix, crossed the granulation of 60 mesh sieves, 40 DEG C of drying are taken out after 2 hours, cross 60 mesh sieve whole grains, main ingredient L- salt in survey particle
The content of sour lysine, it is according to dosage filling in hard shell capsules, packaging, examine, obtain product.
The children's compound lysine of embodiment 3 ties up the preparation of calcium capsule agent, (prescription:1000):LYS 83g,
The hydrate 50g of calcium monohydrogen phosphate 2, vitamin D278000 units, vitamin B10.70g, vitamin B20.50g, vitamin C
33.8g;Preparation technology:Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves LYS and calcium monohydrogen phosphate 2 be hydrated
Thing, vitamin B1, vitamin B2, vitamin C be well mixed according to equal increments method, take the vitamin D of recipe quantity2Add appropriate
Absolute ethyl alcohol make dissolving, the solution that concentration is about 1mg/ml is made, above-mentioned solution is uniformly added into raw material fine powder, mix,
The granulation of 60 mesh sieves is crossed, 45 DEG C of drying are taken out after 2 hours, cross 60 mesh sieve whole grains, LYS and phosphoric acid in survey particle
The content of the hydrate of hydrogen calcium 2, it is according to dosage filling in hard shell capsules after qualified, packaging, examine, obtain product.
The children's compound lysine of embodiment 4 ties up the preparation (prescription of calcium capsule agent:1000):LYS 70g, phosphorus
The sour hydrate 58g of hydrogen calcium 2, vitamin D288000 units, vitamin B10.85g, vitamin B20.42g, vitamin C
27.8g, magnesium stearate 1g;Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves LYS and the water of calcium monohydrogen phosphate 2
Compound, vitamin B1, vitamin B2, vitamin C be well mixed according to equal increments method, take the vitamin D of recipe quantity2Add suitable
The absolute ethyl alcohol of amount makes dissolving, and the solution that concentration is about 1mg/ml is made, above-mentioned solution is uniformly sprayed into raw material fine powder, mixes
It is even, the granulation of 60 mesh sieves is crossed, 45 DEG C of drying are taken out after 1 hour, 60 mesh sieves of mistake after the magnesium stearate with crossing 100 mesh sieves mixes,
The content of main ingredient LYS in particle is surveyed, it is according to dosage filling in hard shell capsules, packaging, examine, obtain product.
The children's compound lysine of embodiment 5 ties up the preparation prescription (prescription of calcium capsule agent:1000):L- Lysine Acetates
43.47g, the hydrate 27g of calcium monohydrogen phosphate 2, vitamin D240000 units, vitamin B10.385g, vitamin B20.23g, dimension
Raw plain C 15.4g;Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves L- Lysine Acetates and the hydrate of calcium monohydrogen phosphate 2,
Vitamin B1, vitamin B2, vitamin C be well mixed according to equal increments method, take the vitamin D of recipe quantity2Add appropriate nothing
Water-ethanol makes dissolving, and the solution that concentration is about 0.8mg/ml is made, above-mentioned solution is uniformly sprayed into raw material fine powder, mixes, will
Solid softwood is crossed 60 mesh sieves and pelletized twice, is taken out after 45 DEG C of dry 1h, crosses 60 mesh sieve whole grains, filling in hard shell capsules according to quantity, bag
Dress, examine, obtain product.
The children's compound lysine of embodiment 6 ties up the preparation (prescription of calcium capsule agent:1000):L- Lysine Acetates
86.95g, the hydrate 54g of calcium monohydrogen phosphate 2, vitamin D280000 units, vitamin B1Monohydrate 0.77g is (with without hydrate
Weight calculation amount), vitamin B20.46g, vitamin C 30.8g;Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves L- vinegar
Sour lysine, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C be well mixed according to equal increments method, take place
The vitamin D just measured2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 1mg/ml is made, above-mentioned solution is sprayed
Enter in raw material fine powder, mix, crossed the granulation of 60 mesh sieves, taken out after 45 DEG C of dry 1h, cross 60 mesh sieve whole grains, survey L- vinegar in particle
The content of sour lysine, it is according to dosage filling in hard shell capsules, packaging, examine, obtain product.
The children's compound lysine of embodiment 7 ties up the preparation (prescription of calcium capsule agent:1000):Lysine 30.08g, phosphoric acid
The hydrate 27g of hydrogen calcium 2, vitamin D240000 units, vitamin B10.385g, vitamin B20.23g, vitamin C
15.4g;Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves lysine, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, dimension life
Plain B2, vitamin C is well mixed according to equal increments method;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving,
The solution that concentration is about 1mg/ml is made, above-mentioned solution is uniformly sprayed into raw material fine powder, mixes, is crossed the granulation of 40 mesh sieves,
50 DEG C of dryings are taken out after 45 minutes, cross 60 mesh sieve whole grains, filling in hard shell capsules according to quantity, packaging, are examined, are obtained product.
The children's compound lysine of embodiment 8 ties up the preparation (prescription of calcium capsule agent:1000):1B 31g, phosphoric acid hydrogen
The hydrate 27g of calcium 2, vitamin D240000 units, vitamin B10.385g, vitamin B20.23g, vitamin C 15.4g;
Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves 1B, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2、
Vitamin C is well mixed according to equal increments method;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, is made
The solution that concentration is about 1.5mg/ml, above-mentioned solution is uniformly sprayed into raw material fine powder, mixed, crossed 80 mesh sieves and pelletized, 45
DEG C dry 1 hour after take out, cross 60 mesh sieve whole grains, it is according to dosage filling in hard shell capsules, packaging, examine, obtain product.
The children's compound lysine of embodiment 9 ties up the preparation (prescription of calcium granule:1000 bags):LYS 38.5g,
The hydrate 27g of calcium monohydrogen phosphate 2, vitamin D240000 units, vitamin B1Monohydrate 0.385g without hydrate (to count weight
Amount), vitamin B20.23g, vitamin C 15.4g, sucrose 3000g;Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves
LYS and the hydrate of calcium monohydrogen phosphate 2, vitamin B1Monohydrate, vitamin B2, vitamin C, sucrose, according to etc.
Amount incremental method is well mixed, and takes the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and it is about 250 μ that concentration, which is made,
G/ml solution, then solution is uniformly sprayed into supplementary material fine powder, fully mix, crossed 40 mesh sieves and pelletized, 50 DEG C of dry 2h,
After 40 mesh sieve whole grains, the content of main ingredient LYS in particle is surveyed, it is according to dosage filling in double aluminum composite membrane packaging bags,
Sealing, examine, obtain product.
Preparation (the prescription of the children's compound 1B granule of embodiment 10:1000 bags):LYS 77g, phosphorus
The sour hydrate 54g of hydrogen calcium 2, vitamin D280000 units, vitamin B10.77g, vitamin B20.46g, vitamin C
30.8g;Sucrose 2000g, carmine 0.67g, orange essence 0.5ml;Preparation technology:Take recipe quantity, cross 100 mesh sieves respectively
Solid 1B, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, sucrose, famille rose, passed according to equivalent
Increasing method is well mixed;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and it is about 800 μ g/ml that concentration, which is made,
Solution, then orange essence is added in solution and mixed, above-mentioned solution is uniformly sprayed into supplementary material fine powder, mixed, by it
Cross the granulation of 40 mesh sieves, 50 DEG C of drys 2h, after 40 mesh sieve whole grains, the content of main ingredient LYS in survey particle, according to dosage
It is filling in double aluminum composite membrane packaging bags, sealing, examine, obtain finished product.
The children's compound lysine of embodiment 11 ties up the preparation (prescription of calcium granule:1000 bags):LYS 154g,
The hydrate 108g of calcium monohydrogen phosphate 2, vitamin D2160000 units, vitamin B11.54g vitamin B20.92g, vitamin C
61.6g, xylitol 200g;Preparation technology:LYS and calcium monohydrogen phosphate 2 that take recipe quantity, crossing respectively after 60 mesh sieves
Hydrate, vitamin B1, vitamin B2, vitamin C, xylitol be well mixed according to equal increments method;Take the vitamin of recipe quantity
D2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 2mg/ml is made, and above-mentioned solution is uniformly sprayed into supplementary material
In fine powder, mix, crossed 60 mesh sieves, particle is made, 45 DEG C of dry 1h, after 60 mesh sieve whole grains, surveys main ingredient L- salt in particle
The content of sour lysine, it is according to dosage filling in double aluminum composite membrane packaging bags, sealing, examine, obtain finished product.
The compound lysine of embodiment 12 ties up the preparation (prescription of calcium granule:1000 bags):LYS 164g, phosphoric acid
The hydrate 115g of hydrogen calcium 2, vitamin D2170000 units, vitamin B11.45g vitamin B20.84g, vitamin C
56.6g, xylitol 200g;Preparation technology:LYS and phosphoric acid hydrogen that take recipe quantity, crossing respectively after 40~60 mesh sieves
The hydrate of calcium 2, vitamin B1, vitamin B2, vitamin C, xylitol, be well mixed according to equal increments method;Take the dimension of recipe quantity
Raw plain D2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 2.5mg/ml is made, and above-mentioned solution is sprayed into former auxiliary
Expect in fine powder, mix, crossed the granulation of 60 mesh sieves, about 45 DEG C of dry 2h, then cross 60 mesh sieve whole grains, survey main ingredient L- salt in particle
The content of sour lysine, it is according to dosage filling in double aluminum composite membrane packaging bags, sealing, examine, obtain finished product.
Preparation (the prescription of the compound lysine vitamin calcium granule of embodiment 13:1000 bags):LYS 142g,
The hydrate 100g of calcium monohydrogen phosphate 2, vitamin D2145000 units, vitamin B11.60g vitamin B21.0g, vitamin C
68.8g, saccharin sodium 5g, xylitol 100g;Preparation technology:Take recipe quantity, respectively cross 40~60 mesh sieves, take sieving after L- salt
The sour hydrate of lysine and calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, saccharin sodium, xylitol is according to equal increments
Method is well mixed;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and it is about the molten of 2mg/ml that concentration, which is made,
Liquid, above-mentioned solution is sprayed into supplementary material fine powder, mixed, crossed the granulation of 40 mesh sieves, 45 DEG C or so dry 1.5h, cross 40 mesh sieves
Whole grain, the content of main ingredient LYS in particle is surveyed, is according to dosage sub-packed in double aluminum composite membrane packaging bags, sealing, examines,
Obtain finished product.
Preparation (the prescription of the children's compound lysine supensoid agent of embodiment 14:1000 bags):LYS 77g, phosphoric acid
The hydrate 54g of hydrogen calcium 2, vitamin D280000 units, vitamin B10.77g, vitamin B20.46g, vitamin C 30.8g,
Xylitol 500g, xanthans 5g;Preparation technology:LYS and phosphoric acid hydrogen that take recipe quantity, crossing respectively after 80 mesh sieves
The hydrate of calcium 2, vitamin B1, vitamin B2, vitamin C, xylitol, xanthans, be well mixed according to equivalent dilution method of progressively increasing;
Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 0.8mg/ml is made, will be above-mentioned
Solution is sprayed into supplementary material fine powder, is mixed, and is crossed 40 mesh sieves and pelletized, and after 45 DEG C or so dry 3h, crosses 40 mesh sieve whole grains, survey
The content of LYS in grain, according to dosage it is sub-packed in double aluminum composite membrane packaging bags, sealing, examines, obtain finished product.
Preparation (the prescription of the children's compound lysine supensoid agent of embodiment 15:1000 bags):L- Lysine Acetates 86.95g, phosphorus
The sour hydrate 54g of hydrogen calcium 2, vitamin D280000 units, vitamin B10.77g, vitamin B20.46g, vitamin C
30.8g, xylitol 500g, xanthans 5g;Preparation technology:Take recipe quantity, respectively cross 80 mesh sieves after L- Lysine Acetates and
The hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, xylitol, and cross 100 mesh sieves xanthans, according to etc.
Dilution method of progressively increasing is measured to be well mixed;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and concentration is made and is about
0.8mg/ml solution, above-mentioned solution is sprayed into supplementary material fine powder, mixed, crossed the granulation of 60 mesh sieves, 50 DEG C or so dryings
After 2h, 60 mesh sieve whole grains are crossed, survey the content of L- Lysine Acetates in particle, are according to dosage sub-packed in double aluminum composite membrane packaging bags,
Sealing, examine, obtain finished product.
Preparation (the prescription of the children's compound 1B granule of embodiment 16:1000 bags):L- Lysine Acetates 43.47g,
The hydrate 27g of calcium monohydrogen phosphate 2, vitamin D240000 units, vitamin B10.385g, vitamin B20.23g, vitamin C
15.4g, STEVIA REBAUDIANA element 0.3g, xylitol 200g;Preparation technology:Take recipe quantity, respectively cross 80 mesh sieves after L- acetic acid rely ammonia
Acid and the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, STEVIA REBAUDIANA element, xylitol, mixed according to equal increments method
Close uniform;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 0.8mg/ml is made,
Above-mentioned solution is sprayed into raw material fine powder, mixed, is crossed the granulation of 40 mesh sieves, 50 DEG C or so drying are taken out after 2 hours, 40 mesh of mistake
Whole grain is sieved, is according to dosage sub-packed in double aluminum composite membrane packaging bags, sealing, is examined, obtain corresponding preparation.
Preparation (the prescription of the children's compoundL -lysine granules agent of embodiment 17:1000 bags):L- Lysine Acetates 86.95g, phosphorus
The sour hydrate 54g of hydrogen calcium 2, vitamin D280000 units, vitamin B1Monohydrate 0.77g (with without hydrate weight calculation amount), dimension
Raw plain B20.46g, vitamin C 30.8g, sorbierite 1000g;Preparation technology:L- taking recipe quantity, crossing respectively after 60 mesh sieves
Lysine Acetate, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, sorbierite, mixed according to equal increments method
Uniformly;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 1.5mg/ml is made, will
Above-mentioned solution is sprayed into supplementary material fine powder, is mixed, and is crossed the granulation of 60 mesh sieves, is taken out after 50 DEG C or so dry 1.5h, cross 60 mesh
Whole grain is sieved, surveys the content of L- Lysine Acetates in particle, is according to dosage sub-packed in double aluminum composite membrane packaging bags, sealing, is examined, obtain
Finished product.
The compound lysine of embodiment 18 ties up the preparation (prescription of calcium granule:1000 bags):L- Lysine Acetates 174g, phosphoric acid
The hydrate 108g of hydrogen calcium 2, vitamin D2160000 units, vitamin B11.54g vitamin B20.92g, vitamin C
61.6g, Sucralose 1g, methylcellulose 2g, xylitol 200g;Preparation technology:Take recipe quantity, respectively cross 40~60 mesh sieves
L- Lysine Acetates and the hydrate of calcium monohydrogen phosphate 2, vitamin B afterwards1, vitamin B2, vitamin C, Sucralose, Methyl cellulose
Element, xylitol, are well mixed according to equal increments method;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving,
The solution that concentration is about 1.5mg/ml is made, above-mentioned solution is sprayed into supplementary material fine powder, mixes, is crossed the granulation of 40 mesh sieves,
45 DEG C or so dryings are taken out after 2 hours, cross 40 mesh sieve whole grains, are surveyed the content of L- Lysine Acetates in particle, are according to dosage sub-packed in
In double aluminum composite membrane packaging bags, sealing, examine, obtain finished product.
The compound lysine of embodiment 19 ties up the preparation (prescription of calcium granule:1000 bags):L- Lysine Acetates 261g, phosphoric acid
The hydrate 162g of hydrogen calcium 2, vitamin D2240000 units, vitamin B12.31g vitamin B21.38g vitamin C
92.4g, hydroxypropyl cellulose 8g, xylitol 2000g;Preparation technology:Take recipe quantity, respectively cross 60 mesh sieves after L- acetic acid rely
Propylhomoserin, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, hydroxypropyl cellulose, xylitol, passed according to equivalent
Increasing method is well mixed;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and it is about 2mg/ml's that concentration, which is made,
Solution, above-mentioned solution is sprayed into supplementary material fine powder, mixed, crossed the granulation of 40 mesh sieves, after 50 DEG C or so the dryings 2 hours of making thinner
Take out, cross 40 mesh sieve whole grains, be sub-packed in respectively according to different dosage strengths in double aluminum composite membrane packaging bags, sealing, examine, obtain
Corresponding preparation.
The compound lysine of embodiment 20 ties up the preparation (prescription of calcium granule:1000 bags):L- Lysine Acetates 261g, phosphoric acid
The hydrate 154g of hydrogen calcium 2, vitamin D2220000 units, vitamin B12.51g vitamin B21.50g vitamin C
85.0g, xanthans 5g, xylitol 3000g;Preparation technology:Take recipe quantity, respectively cross 40~60 mesh sieves after L- acetic acid rely ammonia
Acid and the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, xanthans, xylitol, mixed according to equal increments method
Uniformly;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 1.6mg/ml is made, will
Above-mentioned solution is sprayed into supplementary material fine powder, is mixed, and is crossed the granulation of 60 mesh sieves, is taken out after 45 DEG C or so the dry 2h that make thinner, survey
The content of L- Lysine Acetates in grain, according to dosage it is sub-packed in double aluminum composite membrane packaging bags, sealing, examines, obtain finished product.
The compound lysine of embodiment 21 ties up calcium tablet (prescription:1000):LYS 77g, calcium monohydrogen phosphate 2 are hydrated
Thing 54g, vitamin D280000 units, vitamin B10.77g, vitamin B20.46g, vitamin C 30.8g, microcrystalline cellulose
Plain 80g, low-substituted hydroxypropyl cellulose 5g, Aspartame 1g, superfine silica gel powder 2g, 5% polyvinylpyrrolidone are appropriate;
Preparation technology:LYS, the calcium monohydrogen phosphate 2 for taking after crushing respectively and crossing the recipe quantity of 100 mesh sieves are hydrated
Thing, vitamin B1, vitamin B2, vitamin C, vitamin D2, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, Aspartame press
Mixed according to equivalent dilution method of progressively increasing, then with 5% polyvinylpyrrolidone (about 95% alcohol water) solution softwood processed in right amount, mistake
40 mesh sieves are pelletized, 50 DEG C or so forced air dryings 2 hours, and after crossing 40 mesh sieve whole grains, the superfine silica gel powder with crossing 100 mesh sieves mixes;Will
It crosses 40 mesh sieves, whole grain, detects L- Lysine Acetate contents in intermediate, tabletting, packs and produce.
The compound lysine of embodiment 22 ties up calcium tablet (prescription:1000):LYS 154g, the water of calcium monohydrogen phosphate 2
Compound 108g, vitamin D2160000 units, vitamin B11.54g vitamin B20.92g, vitamin C 61.6g, crystallite
Cellulose 300g, substitution hydroxypropyl cellulose 30g, micro- magnesium stearate 5g, 5% polyvinylpyrrolidone are appropriate;
Preparation technology:LYS, the calcium monohydrogen phosphate 2 for taking after crushing respectively and crossing the recipe quantity of 100 mesh sieves are hydrated
Thing, vitamin B1, vitamin B2, vitamin C, microcrystalline cellulose, substitution hydroxypropyl cellulose be well mixed;Take the dimension of recipe quantity
Raw plain D2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 2mg/ml is made, and above-mentioned solution is sprayed into supplementary material
In fine powder, mix, with 5% polyvinylpyrrolidone (about 90% alcohol water) solution softwood processed in right amount, cross the granulation of 40 mesh sieves,
50 DEG C or so forced air dryings 2 hours, after crossing 40 mesh sieve whole grains, the magnesium stearate with crossing 100 mesh sieves mixes, and tabletting, packs and produces.
The children's compound lysine of embodiment 23 ties up calcium tablet (prescription:1000):LYS 154g, calcium monohydrogen phosphate
2 hydrate 108g, vitamin D2160000 units, vitamin B11.54g vitamin B20.92g, vitamin C 61.6g, form sediment
Powder 50g, microcrystalline cellulose 100g, low-substituted hydroxypropyl cellulose 20g, superfine silica gel powder 8g, hydroxypropyl methyl cellulose 5g;
Preparation technology:LYS, the calcium monohydrogen phosphate 2 for taking after crushing respectively and crossing the recipe quantity of 100 mesh sieves are hydrated
Thing, vitamin B1, vitamin B2, vitamin C, starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methyl fiber
Element is well mixed;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and it is about 1.8mg/ml's that concentration, which is made,
Solution, above-mentioned solution is sprayed into supplementary material fine powder, mixed, about 2mm thin strip dry plate, mistake are pressed into dry-pressing formula rubber mixing machine
40 mesh sieves are pelletized, 50 DEG C or so forced air dryings 1 hour, and after crossing 40 mesh sieve whole grains, the superfine silica gel powder with crossing 100 mesh sieves mixes, pressure
Piece, pack and produce.
The children's compound lysine of embodiment 24 ties up the preparation (prescription of calcium tablet:1000):L- Lysine Acetates 86.95g,
The hydrate 54g of calcium monohydrogen phosphate 2, vitamin D280000 units, vitamin B10.77g, vitamin B20.46g, vitamin C
30.8g, lactose 50g, microcrystalline cellulose 200, sodium carboxymethyl starch 40g, superfine silica gel powder 8g, hydroxypropyl methyl cellulose 30g;
Preparation technology:LYS, the calcium monohydrogen phosphate 2 for taking after crushing respectively and crossing the recipe quantity of 100 mesh sieves are hydrated
Thing, vitamin B1, vitamin B2, vitamin C, lactose, microcrystalline cellulose, sodium carboxymethyl starch, hydroxypropyl methyl cellulose mixing
Uniformly;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 2mg/ml is made, will be upper
State solution to spray into supplementary material fine powder, mix, about 2mm thin strip dry plate is pressed into dry-pressing formula rubber mixing machine, cross 40 mesh sieve series
Grain, 50 DEG C or so forced air dryings 1 hour, add the superfine silica gel powder of recipe quantity, mix, after crossing 40 mesh sieve whole grains, with crossing 100 mesh sieves
Superfine silica gel powder mixes, and tabletting, packs and produces.
The children's compound lysine of embodiment 25 ties up the preparation (prescription (1000) of calcium tablet:L- Lysine Acetates 173.9g,
The hydrate 108g of calcium monohydrogen phosphate 2, vitamin D2160000 units, vitamin B11.54g vitamin B20.92g, vitamin C
61.6g, microcrystalline cellulose 200, sodium carboxymethyl starch 30g, superfine silica gel powder 8g, hydroxypropyl methyl cellulose 40g;
Preparation technology:LYS, the calcium monohydrogen phosphate 2 for taking after crushing respectively and crossing the recipe quantity of 100 mesh sieves are hydrated
Thing, vitamin B1, vitamin B2, vitamin C, microcrystalline cellulose, sodium carboxymethyl starch, hydroxypropyl methyl cellulose be well mixed;
Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 4mg/ml is made, will be above-mentioned molten
Liquid is sprayed into supplementary material fine powder, is mixed, and 2mm thin strip dry plate is pressed into dry-pressing formula rubber mixing machine, is crossed 24 mesh sieves and is pelletized, 45 DEG C
Left and right forced air drying 1 hour, after crossing 24 mesh sieve whole grains, the superfine silica gel powder with crossing 100 mesh sieves mixes, and tabletting, packs and produces.
The children's compound lysine of embodiment 26 ties up the preparation (prescription of calcium supensoid agent:1000 bags):Lysine Acetate 173.9g,
The hydrate 108g of calcium monohydrogen phosphate 2, vitamin D2160000 units, vitamin B11.54g vitamin B20.92g, vitamin C
61.6g, xylitol 200g, Sucralose 1g, xanthans 2g;Preparation technology:Original taking recipe quantity, crossing respectively after 100 mesh sieves
Auxiliary material (removes vitamin D2Outside), it is well mixed;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, is made dense
Degree is about 0.8mg/ml solution, and above-mentioned solution is sprayed into supplementary material fine powder by several times, mixed, crosses the granulation of 40 mesh sieves, 50 DEG C of left sides
Right forced air drying 1 hour, after crossing 40 mesh sieve whole grains, it is sub-packed according to quantity in bag, sealing, examines, obtain corresponding pharmaceutical composition system
Agent.
The preparation (200 bottles of prescription) of the compound 1B dry suspensoid agent of embodiment 27:L- Lysine Acetates 173.9g, phosphoric acid
The hydrate 108g of hydrogen calcium 2, vitamin D2160000 units, vitamin B11.54g vitamin B20.92g, vitamin C
61.6g, xylitol 100g, Aspartame 5g, xanthans 5g, tragacanth 2g, methylcellulose 3g, lemon yellow 3g;Prepare work
Skill:Take recipe quantity, cross 100 mesh sieves respectively after supplementary material (remove vitamin D by equivalent method of progressively increasing2It is well mixed outside);Take place
The vitamin D just measured2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 2mg/ml is made, by above-mentioned solution point
In secondary penetrating supplementary material fine powder, mix, cross the granulation of 40 mesh sieves, 50 DEG C or so forced air dryings 2 hours, after crossing 40 mesh sieve whole grains, point
Loaded in 200ml bottles, seal, examine, obtain corresponding drug combination preparation.
The preparation (200 bottles of prescription) of the children's compoundL -lysine granules agent of embodiment 28:LYS 38.5g, phosphoric acid
The hydrate 27g of hydrogen calcium 2, vitamin D240000 units, vitamin B10.385g, vitamin B20.23g, vitamin C
15.4g, xylitol 1000g, xanthans 1g;Preparation technology:Take recipe quantity, respectively cross 100 mesh sieves LYS and
The hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin C, xylitol, xanthans, mixed according to equal increments method equal
It is even, take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes dissolving, and the solution that concentration is about 250 μ g/ml is made, then will
Solution is sprayed into supplementary material fine powder, is fully mixed, and is crossed the granulation of 40 mesh sieves, 50 DEG C of dry 2h, after 40 mesh sieve whole grains, by agent
Measure in filling 100ml bottles, seal, examine, obtain product.
Preparation (the prescription of the children's compound 1B granule of embodiment 29:1000 bags):LYS 77g, phosphorus
The sour hydrate 54g of hydrogen calcium 2, vitamin D280000 units, vitamin B10.77g, vitamin B20.46g, vitamin C
30.8g, carmine 0.67g, orange essence 0.5ml, xylitol (being added to makes prescription component weight to 1000g);Preparation technology:
Take recipe quantity, respectively cross 100 mesh sieves solid 1B, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, dimension life
Plain C, xylitol, famille rose, are well mixed according to equal increments method;Take the vitamin D of recipe quantity2Add appropriate absolute ethyl alcohol
Make dissolving, concentration is made and is about 800 μ g/ml solution, then orange essence is added in solution and mixed, above-mentioned solution is uniform
Spray into supplementary material fine powder, mix, crossed the granulation of 40 mesh sieves, 50 DEG C of dry 2h, after 40 mesh sieve whole grains, survey main ingredient in particle
The content of LYS, it is according to dosage filling in double aluminum composite membrane packaging bags, sealing, examine, obtain finished product.
Preparation (the prescription of the children's compound 1B granule of embodiment 30:1000 bags):L- Lysine Acetates 86.95g,
The hydrate 54g of calcium monohydrogen phosphate 2, vitamin D280000 units, vitamin B1Monohydrate 0.77g (weight is in terms of anhydride), dimension
Raw plain B20.46g, vitamin C 30.8g;Xylitol 2000g, carmine 0.67g, orange essence 0.5ml;Preparation technology:Take
Recipe quantity, respectively cross 100 mesh sieves solid 1B, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2, vitamin
C, xylitol, famille rose, are well mixed according to equal increments method;Take the vitamin D of recipe quantity2Adding appropriate absolute ethyl alcohol makes
Dissolving, is made concentration and is about 800 μ g/ml solution, then orange essence is added in solution and mixed, and above-mentioned solution is uniformly sprayed
Enter in supplementary material fine powder, mix, crossed the granulation of 40 mesh sieves, 40 DEG C of dry 2h are according to dosage filling in double after 40 mesh sieve whole grains
In aluminum composite membrane packaging bag, sealing, examine, obtain finished product.
Preparation (the prescription of the children's compound 1B granule of embodiment 31:1000 bags):1B 61.63g, phosphoric acid
The hydrate 54g of hydrogen calcium 2, vitamin D280000 units, vitamin B1Monohydrate 0.77g (weight is in terms of anhydride), vitamin
B20.46g, vitamin C 30.8g;Xylitol 1000g, carmine 0.67g, orange essence 0.5ml;Preparation technology:Take prescription
Solid 1B, the hydrate of calcium monohydrogen phosphate 2, vitamin B measure, crossing 100 mesh sieves respectively1, vitamin B2, vitamin C, wood
Sugar alcohol, famille rose, are well mixed according to equal increments method;Take the vitamin D of recipe quantity2Add appropriate absolute ethyl alcohol make it is molten
Solution, is made concentration and is about 800 μ g/ml solution, then orange essence is added in solution and mixed, and above-mentioned solution is uniformly sprayed into
In supplementary material fine powder, mix, crossed the granulation of 40 mesh sieves, 40 DEG C of dry 2h are according to dosage filling in double aluminium after 40 mesh sieve whole grains
In composite film packaging bag, sealing, examine, obtain finished product.
Preparation (the prescription of the children's compound 1B granule of embodiment 32:1000 bags):LYS 38.5g,
The hydrate 27g of calcium monohydrogen phosphate 2, vitamin D240000 units, vitamin B1Monohydrate 0.385g (weight is in terms of anhydride),
Vitamin B20.23g, vitamin C 15.4g;Xylitol 920g, carmine 0.335g, orange essence 0.25ml;Preparation technology:
Take recipe quantity, respectively cross 100 mesh sieves solid LYS, the hydrate of calcium monohydrogen phosphate 2, vitamin B1, vitamin B2、
Vitamin C, xylitol, famille rose, are well mixed according to equal increments method;Take the vitamin D of recipe quantity2Add in right amount anhydrous
Ethanol makes dissolving, and concentration is made and is about 800 μ g/ml solution, then orange essence is added in solution and mixed, by above-mentioned solution
Uniformly spray into supplementary material fine powder, mix, crossed the granulation of 40 mesh sieves, 50 DEG C of dry 2h, after 40 mesh sieve whole grains, surveyed in particle
The content of main ingredient LYS, it is according to dosage filling in double aluminum composite membrane packaging bags, sealing, examine, obtain finished product.
The rat administration experiments experiment animal of the pharmaceutical composition of embodiment 33:Birth about surrounding or so, body weight about 75~
90 grams, the Wistar male white rats 88 being in a good state of health, ablactation;Rat, which is evenly distributed, according to rat body weight is divided into four
Group, every group of rat n=22 is only so that there was no significant difference for the average weight between each group rat before experiment, and A groups are blank pair
According to group, basal feed raising is given;B, C, D are administration group, give the mixed fodder raising that basal feed adds main ingredient composition, point
Not with every 100g basal feeds drug containing compositions main ingredient weight about 100mg different weight than each correspondent composition powder or
Rat is fed in the mixed fodder of particle;Wherein, B groups are composition group (the main ingredient composition proportioning of DL- lysine hydrochlorides:
77mg/54mg/0.77mg/30.08mg/80 unit, respectively with DL- lysine hydrochlorides and the hydrate of calcium monohydrogen phosphate 2, vitamin
B1, vitamin B2, vitamin C, vitamin D2Count each component weight or unit of weight);C groups are to be combined containing LYS
(main ingredient composition matches thing group:Embodiment 23);D groups are composition group (the main ingredient composition proportioning of the Lysine Acetate containing L-:It is real
Apply example 31);B, C, D each group with basal feed with the composition of each group feed after preparation mixes respectively, and each group is launched daily
Basal feed amount keep impartial, free water and ingest;Every group of rat feeds surrounding, and every rat body weight is claimed before testing, real
Test to 4th week end and claim its body weight, obtain the net gain after four weeks, calculate every group of average, Analysis of variance, as a result find that C, D are each
The difference of experimental group and A groups and B groups has conspicuousness, its p value ﹤ 0.05;Experimental result is shown in Table 1.
The rat administration experimental result of the compound lysine medicament compound of table 1
Industrial applicibility etc. and its explanation etc.:
The present invention is described in detail above by embodiment and embodiment, it will nevertheless be understood that these are said
Bright that any restrictions are not formed to the scope of the present invention, person skilled substantially can be in the spirit without departing from the present invention and guarantor
In the case of protecting scope, technical solutions and their implementation methods of the present invention can be carried out with a variety of modifications, improvement and replacement and group
Close, to realize the technology of the present invention, these are because falling within the scope of protection of the present invention.In particular, it will be understood that
The change of many details is possible, and all similar replacements and change are apparent for a person skilled in the art
, they are considered as being included in the spirit, scope and content of the present invention, and the present invention is not limited to above-described embodiment.
Claims (8)
1. the composition of compound lysine vitamin calcium, it is characterised in that:The said composition of one unit dose or unit formulation
The weight or weight ratio of middle main ingredient component is:LYS 35~231mg or L- Lysine Acetate or Lysine Acetate 40
~261mg or lysine or 1B or 30~185mg of its solvated compounds, calcium monohydrogen phosphate or the hydrate 25 of calcium monohydrogen phosphate 2
~162mg, vitamin D2Or its unit of solvated compoundses 40~240, vitamin B1Or 0.35~2.31mg of its solvated compounds,
Vitamin B2Or 0.20~1.38mg of its solvated compounds, 15.0~92.4mg of vitamin C or its solvated compounds, each component
The weight of solvated compoundses in addition to specifying, to be converted into solvent-free chemical combination when calculated weight.
2. the composition of compound lysine vitamin calcium according to claim 1, it is characterised in that:One unit dose or
The weight of main ingredient component or weight ratio are in the said composition of unit formulation:LYS 38.5~231mg or L- acetic acid
Lysine or 43~261mg of Lysine Acetate or lysine or 30~185mg of 1B or its solvated compounds, calcium monohydrogen phosphate
Or 27~the 162mg of hydrate of calcium monohydrogen phosphate 2, vitamin D2Or its unit of solvated compoundses 40~240, vitamin B1Or its solvent
0.385~2.31mg of compound, vitamin B2Or 0.23~1.38mg of its solvated compounds, vitamin C or its solvated compounds
15.4~92.4mg, and pharmaceutically acceptable one or more auxiliary materials or carrier;Wherein, the solvated compoundses of each component
Weight in addition to specifying, to be converted into solvent-free chemical combination when calculated weight.
3. the composition of compound lysine vitamin calcium according to claims 1 to 2, it is characterised in that:One unit dose
In composition in amount or unit formulation containing LYS or its solvated compounds 38.5mg or L- Lysine Acetates or
Lysine Acetate or its solvated compounds 43.47mg or 43.5mg or 44 or lysine or 1B or its solvated compounds
30.08mg or 30.1mg or 30mg, calcium monohydrogen phosphate or the hydrate 27mg of calcium monohydrogen phosphate 2, vitamin D2Or its solvated compounds 40
Unit, vitamin B1Or its solvated compounds 0.385mg, vitamin B2Or its solvated compounds 0.23mg, vitamin C or its is molten
Immunomodulator compounds 15.4mg, and pharmaceutically acceptable one or more auxiliary materials or carrier;The wherein solvated compoundses of each component
Weight in addition to specifying, to be converted into solvent-free chemical combination when calculated weight.
4. the composition of compound lysine vitamin calcium according to claims 1 to 2, it is characterised in that:One unit dose
Contain LYS or its solvated compounds 77mg or L- Lysine Acetates or vinegar in composition in amount or unit formulation
Sour lysine or its solvated compounds 86.945mg or 86.95mg or 87mg or lysine or 1B or its solvated compounds
61.63mg or 61.6mg or 62mg, calcium monohydrogen phosphate or the hydrate 54mg of calcium monohydrogen phosphate 2, vitamin D2Or its solvated compounds 80
Unit, vitamin B1Or its solvated compounds 0.77mg, vitamin B2Or its solvated compounds 0.46mg, vitamin C or its solvent
Compound 30.8mg, and pharmaceutically acceptable one or more auxiliary materials or carrier;Wherein, the solvated compoundses of each component
Weight in addition to specifying, to be converted into solvent-free chemical combination when calculated weight.
5. the composition of compound lysine vitamin calcium according to claims 1 to 2, it is characterised in that:One unit dose
Contain LYS or its solvated compounds 154mg or L- Lysine Acetates or vinegar in composition in amount or unit formulation
Sour lysine or its solvated compounds 173.89mg or 173.9mg or 174mg or lysine or 1B 123.26mg or
123.3mg or 123mg, calcium monohydrogen phosphate or the hydrate 108mg of calcium monohydrogen phosphate 2, vitamin D2Or its unit of solvated compoundses 160,
Vitamin B1Or its solvated compounds 1.54mg, vitamin B2Or its solvated compounds 0.92mg, vitamin C or its solvent chemical combination
Thing 61.6mg, and pharmaceutically acceptable one or more auxiliary materials or carrier;Wherein, the weight of the solvated compoundses of each component
In addition to specifying, to be converted into solvent-free chemical combination when calculated weight.
6. the composition of compound lysine vitamin calcium according to claims 1 to 2, it is characterised in that:One unit dose
Contain LYS or its solvated compounds 231mg or L- Lysine Acetates or vinegar in composition in amount or unit formulation
Sour lysine or its solvated compounds 260.83mg or 260.8mg or 261mg or lysine or 1B or its solvent chemical combination
Thing 184.89mg or 184.9mg or 185mg, calcium monohydrogen phosphate or the hydrate 162mg of calcium monohydrogen phosphate 2, vitamin D2Or its solvation
The unit of compound 240, vitamin B1Or its solvated compounds 2.31mg, vitamin B2Or its solvated compounds 1.38mg, vitamin C
Or its solvated compounds 92.4mg, and pharmaceutically acceptable one or more auxiliary materials or carrier;Wherein, the solvent of each component
The weight of compound in addition to specifying, to be converted into solvent-free chemical combination when calculated weight.
7. the composition of compound lysine vitamin calcium according to claims 1 to 6, it is characterised in that:Its purposes is:Should
Composition individually or the application with pharmaceutically acceptable auxiliary material in tablet, granule, capsule, supensoid agent is prepared.
8. the composition of compound lysine vitamin calcium according to claims 1 to 6, it is characterised in that:Its purposes is:
Prepare prevention or treatment people and mammal lysine shortage, hypovitaminosis, calcium deficiency, retarded growth, rickets, bone
Application in the health food or medicine of matter osteoporosis and enhancing development.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610843576.3A CN107854487A (en) | 2016-09-22 | 2016-09-22 | Children's compound lysine vitamin calcium medicine compound comprising chiral photo-isomerisation compound and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610843576.3A CN107854487A (en) | 2016-09-22 | 2016-09-22 | Children's compound lysine vitamin calcium medicine compound comprising chiral photo-isomerisation compound and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107854487A true CN107854487A (en) | 2018-03-30 |
Family
ID=61699014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610843576.3A Withdrawn CN107854487A (en) | 2016-09-22 | 2016-09-22 | Children's compound lysine vitamin calcium medicine compound comprising chiral photo-isomerisation compound and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107854487A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113797311A (en) * | 2021-09-22 | 2021-12-17 | 海南葫芦娃药业集团股份有限公司 | Multivitamin calcium zinc selenium granules for children and preparation method thereof |
-
2016
- 2016-09-22 CN CN201610843576.3A patent/CN107854487A/en not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113797311A (en) * | 2021-09-22 | 2021-12-17 | 海南葫芦娃药业集团股份有限公司 | Multivitamin calcium zinc selenium granules for children and preparation method thereof |
CN113797311B (en) * | 2021-09-22 | 2024-01-16 | 海南葫芦娃药业集团股份有限公司 | Multi-vitamin calcium zinc selenium granule for children and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005256317B2 (en) | Compositions comprising strontium and vitamin D and uses thereof | |
RU2460340C2 (en) | Vitamin and mineral additives stability enhancement | |
US20190269614A1 (en) | Chewable tablet containing vitamin c sodium and preparation method thereof | |
US20100008865A1 (en) | Mixture of iron and copper salts masking metallic taste | |
CN101282735A (en) | Mixture of iron and copper salts masking mettalic taste | |
US10251909B2 (en) | Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension | |
US6447807B1 (en) | Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery | |
AU2004255466A1 (en) | Pharmaceutical formulation comprising levothyroxine sodium | |
CN103417489A (en) | Calcium gluconate zinc gluconate particulate agent preparation method | |
US20170157001A1 (en) | Compositions Comprising Strontium and Uses Thereof in the Treatment or Prevention of Gingivitis, Periodontitis, Periodontitis as a Manifestation of Systemic Diseases, and Necrotizing Periodontal Diseases | |
CN104739816B (en) | Bad Portugal's zinc medical composition and its use including chiral photo-isomerisation compound | |
CN101716180B (en) | Combined medicament for supplementing zinc and calcium and preparation method thereof | |
CN107854487A (en) | Children's compound lysine vitamin calcium medicine compound comprising chiral photo-isomerisation compound and application thereof | |
SK4982000A3 (en) | Pharmaceutical composition with a content of calcium or mixture of calcium and vitamin d or mixture of calcium and magnesium in a new formulation | |
CN104840800B (en) | Bamboo-leaves flavones and the composition of γ-aminobutyric acid and its preparation method and application | |
CN104688774A (en) | Lysine and calcium hydrophosphate pharmaceutical composition comprising chiral isomeric compound and application of pharmaceutical composition | |
CN109090319A (en) | Newborn mineral salt pressed candy | |
CN103655574A (en) | Compound ferrous succinate and folic acid composition | |
CN106176756A (en) | The lysine five comprising chiral photo-isomerisation compound ties up medical composition and its use | |
CN104688763A (en) | Lysine-vitamin pharmaceutical composition containing chiral isocompounds and use thereof | |
WO1996004917A1 (en) | Remedy for myotonic dystrophy | |
JPH0476971B2 (en) | ||
WO2019119445A1 (en) | Nadh compound, and formulation and application thereof | |
CN107854457A (en) | Calcium gluconate Zn composition including chiral photo-isomerisation compound and application thereof | |
CN104857002B (en) | The medical composition and its use of lysine vitamin comprising chiral photo-isomerisation compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180330 |
|
WW01 | Invention patent application withdrawn after publication |